You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Unlike existing methods for sepsis diagnosis, which rely on the use of a single marker, Mologic's technology is based on six undisclosed markers.
The firm said that investigators will evaluate the clinical benefit of its assay using blood samples from a clinical trial for women with metastatic hormone receptor-positive breast cancer.
The firm anticipates that point-of-care adoption may attract licensing deals from companies interested in adding the biomarkers to their large laboratory analyzers.
The German firm said that IB10 Sphingotec DPP3 is the first CE-IVD-marked point-of-care biomarker test that can quantify DPP3 blood plasma levels.
The firm said that its lateral flow test may enable sports teams and paramedics to quickly decide whether there's a concussion or not.
When blood amyloid levels are combined with other risk factors, people with early Alzheimer's brain changes can be identified with high accuracy.
Ortho's assay, which aids in quickly and accurately diagnosing heart attacks, runs on its new Vitros XT 7600 Integrated System, among other Ortho systems.
The combined company will offer laboratory testing and digital technologies for diagnosing and managing lupus, multiple sclerosis, and other autoimmune diseases.
The German firm, spun off from a marine research institute, recently closed a €1 million seed financing round to support expansion of the company and drive adoption.
The firm said that with the approval, the firm's liquid biopsy-based ExoDx Prostate IntelliScore (EPI) test is now available in every state.